Marinus Pharma

Marinus will be hosting an Investor and Analyst Event on September 20 in New York and via webcast. Learn more about the event and how to register: https://lnkd.in/e4p8TFMv

We were honored to host Carly at our TSC Town Hall, where she shared insights into her life as a caregiver for her son Logan, who is living with TSC. The TSC patient journey is complex, and their story highlighted both the challenges, and the remarkable resilience involved. Thank you for sharing your experiences, which remind us of the importance of our work and inspire us to continue striving for better treatments and support.

Hosted by the Epilepsy Foundation Eastern Pennsylvania, Marinus was a proud sponsor of Camp Achieve, a summer camp tailored to the unique needs of kids living with epilepsy. Yesterday, our Marinus team volunteered at the Camp Olympics, a day of team-building and friendly competition with the campers. See the photo!

Today, we reported our Q2 2024 earnings and business updates. Learn more in our press release: https://lnkd.in/e7nrntqx

We are honored that ZTALMY® has been nominated for the prestigious #PrixGalien USA award for Best Product for Rare/Orphan Diseases! This program honors the leading-edge of scientific advances in life sciences. Learn more about this recognition: https://lnkd.in/epNd_PPn

Marinus is celebrating a decade of progress! Today marks 10 years since our IPO, and to honor this milestone, we’re spotlighting 10 pivotal moments that have shaped our journey. From pioneering innovative medicines to expanding our global reach, each achievement has been a steppingstone toward our vision. Here's to the past 10 years and to many more milestones ahead!

Today, we are talking about #CDKL5 deficiency disorder, also known as CDD, one of the most common genetic epilepsies. Learn more about the condition and some of the early clinical signs:

In honor of #NationalInternDay, we are highlighting our fantastic interns who are part of our Early Talent Program!     We are thankful to Life Science Cares Philadelphia and Project Onramp for facilitating the connection with our interns and for their support in guiding students towards pursuing a career in #LifeSciences.    Check out what our interns have to say about working at Marinus: 

Today, we announced that our treatment for seizures associated with CDKL5 deficiency disorder is now approved in China for patients two years of age and older. Learn more in our press release: https://lnkd.in/ePAMGRxi

Our team enjoyed their time at the 9th International Lennox-Gastaut Syndrome (LGS) Foundation Family & Professional Conference, where more than 350 family members and medical professionals came together to discuss ways we can improve the quality of life for those with rare seizure disorders.